CBMX
CombiMatrix Corporation
NasdaqCM
People also watch:NANXACTGALTITINYFEIC
3.510.13 (3.85%)

After hours: 4.010.50 (14.25%) as of 7:54 PM EDT

Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close3.38
Open3.35
Bid3.80 x 800
Ask4.15 x 200
52wk Range2.62 - 24.60
Day's Range3.34 - 3.55
Volume50,218
Avg Vol (3m)95,574
As of 4:00 PM EDT. Market closed.
  • Zacks Small Cap Research26 days ago

    CBMX: Largest Study To-Date Further Supports Superiority of CMA

    While several studies over the last number of years, including the widely cited Reddy et al and Wapner et al studies which have positively influenced reimbursement policy, have all indicated  that chromosomal microarray analysis (CMA) is the preferred genetic testing modality versus karyotyping due to the former's proven greater accuracy, that it provides more substantive clinical information and is able to be used on fresh as well as preserved (i.e.

  • CombiMatrix Corp. :CBMX-US: Earnings Analysis: Q1, 2016 By the Numbers
    Capital Cube2 months ago

    CombiMatrix Corp. :CBMX-US: Earnings Analysis: Q1, 2016 By the Numbers

    Click here to see latest analysisCombiMatrix Corp. reports financial results for the quarter ended March 31, 2016.We analyze the earnings along side the following peers of CombiMatrix Corp. – Laboratory Corporation of America Holdings, Sequenom, Inc., Quest Diagnostics Incorporated and NeoGenomics, Inc. (LH-US, SQNM-US, DGX-US and NEO-US) that have also reported for this period.HighlightsSummary numbers: […] (Read more...) The post CombiMatrix Corp. :CBMX-US: Earnings Analysis: Q1, 2016 By the Numbers appeared first on CapitalCube.